Biomerica's inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026

Stock Information for Biomerica Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biomerica Inc.

Biomerica Announces $2.23 Million Financing 
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
Biomerica Reports Third Quarter Fiscal 2026 Financial Results
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect(TM)) from One of the Largest Clinical Laboratory Chains in Europe
Biomerica Receives MHRA Registration for hp+detect(TM), Allowing Commercial Sales in Great Britain
Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.